Chinese Journal of Pharmacovigilance ›› 2026, Vol. 23 ›› Issue (1): 42-49.
DOI: 10.19803/j.1672-8629.20250594

Previous Articles     Next Articles

Treatment of Hypertensive Cardiac Hypertrophy with Siwei Tumuxiang Powder Based on Tissue Non-Targeted Metabolomics

REN Zhongjie1,2, WEI Minghui3, YIN Dongjie1,2, GUO Ying1,2, LU Ziyu1,2, YU Yang1, GUO Yuting1,2, ZHANG Xin1, LIU Fangbing4, ZHANG Jiaru4, WANG Minjie1, XUE Mingming1,*   

  1. 1School of Basic Medical Sciences, Inner Mongolia Medical University, Hohhot Inner Mongolia 010059, China;
    2Laboratory of Medical Neurobiology, School of Basic Medical Sciences, Inner Mongolia Medical University, Hohhot Inner Mongolia 010059, China;
    3Laboratory and Experimental Equipment Management Center, Inner Mongolia Medical University, Hohhot Inner Mongolia 010059, China;
    4The Second Affiliated Hospital, Inner Mongolia Medical University, Hohhot Inner Mongolia 010110, China
  • Received:2025-08-26 Online:2026-01-15 Published:2026-01-15

PDF (PC)

2

Abstract: Objective To investigate the mechanism through which Siwei Tumuxiang powder (STP) intervenes in hypertensive cardiac hypertrophy (HCH) in rats. Methods Forty Sprague-Dawley (SD) rats were randomly divided into four groups (n=10 each): the sham-operated (Sham) group, model (Mod) group, STP group (1.6 g·kg-1), and positive control captopril (CAP) group (0.015 g·kg-1). The last three groups underwent abdominal aortic coarctation (AAC) to induce HCH while the Sham group received abdominal aortic isolation without ligation. Concurrently, the STP and CAP groups were subjected to eight weeks of interventions with STP and CAP, whereas the Sham and Mod groups received 0.9% saline solution via gavage. After 8 weeks, cardiac function was assessed using echocardiography. Pathological changes in cardiac tissues were observed using hematoxylin-eosin (HE) and Masson staining. The mRNA expression levels of hypertrophy markers β-myosin heavy chain (β-MHC) and the myocardial fibrosis marker transforming growth factor-β (TGF-β) were measured using real-time quantitative polymerase chain reaction (RT-qPCR). Protein expression levels of β-MHC and TGF-β were determined by Western blot (WB). Additionally, metabolomic analysis was conducted. Results Compared to the Sham group, the ventricular wall thickened, cardiac function impaired, myocardial fibrosis and inflammatory infiltration became more pronounced, and mRNA and protein expression levels of β-MHC and TGF-β were elevated in the Mod group. In contrast, significant improvements in these indexes were observed in the STP group. Untargeted metabolomics identified 13 differential metabolites and implicated 14 pathways, including arachidonic acid metabolism and the tricarboxylic acid cycle (TCA). Conclusion STP exerts therapeutic effects against HCH and metabolic disorders through multi-target interventions, possibly by regulating energy metabolism and suppressing inflammatory responses.

Key words: Hypertensive Cardiac Hypertrophy, Abdominal Aortic Coarctation, Siwei Tumuxiang Powder, Metabolomics, Rat

CLC Number: